• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Neumann Clarke covered exercise/tax liability with 4,529 shares, decreasing direct ownership by 0.83% to 542,398 units to satisfy tax liability

    11/16/22 9:49:15 PM ET
    $PROG
    Specialty Chemicals
    Consumer Durables
    Get the next $PROG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    NEUMANN CLARKE

    (Last) (First) (Middle)
    C/O BIORA THERAPEUTICS, INC.
    4330 LA JOLLA VILLAGE DRIVE, SUITE 300

    (Street)
    SAN DIEGO CA 92122

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIORA THERAPEUTICS, INC. [ BIOR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    11/15/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/15/2022 F 4,529(1) D $0.27 542,398 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 13,094 vested restricted stock units on November 15, 2022.
    Remarks:
    Senior Vice President, General Counsel and Secretary
    /s/ Will Pridgen, Attorney-in-Fact for Clarke Neumann 11/16/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PROG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROG

    DatePrice TargetRatingAnalyst
    11/4/2021$59.00 → $57.00Overweight → Equal-Weight
    Stephens
    10/14/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PROG
    Financials

    Live finance-specific insights

    See more
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code:

      3/16/22 4:23:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 9763335. A live webcast and archive of the call will be available online from the investor relations section of the compa

      11/3/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      1/12/23 4:46:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      11/18/22 4:30:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13G/A filed by Progenity Inc. (Amendment)

      SC 13G/A - PROGENITY, INC. (0001580063) (Subject)

      2/14/22 3:32:06 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    SEC Filings

    See more
    • Progenity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/20/23 4:05:58 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/12/23 6:06:03 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/9/23 4:02:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progenity downgraded by Stephens with a new price target

      Stephens downgraded Progenity from Overweight to Equal-Weight and set a new price target of $57.00 from $59.00 previously

      11/4/21 7:18:22 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • HC Wainwright & Co. initiated coverage on Progenity with a new price target

      HC Wainwright & Co. initiated coverage of Progenity with a rating of Buy and set a new price target of $4.00

      10/14/21 6:20:58 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity downgraded by Raymond James

      Raymond James downgraded Progenity from Outperform to Market Perform

      6/3/21 7:08:09 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progenity Announces Successful Transfer of Liquid Biopsy Technologies

      SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy. Under the terms of the agreement, Progenity is contributing all assets related to the technologies to newly formed Enumera Molecular, Inc., which intends to develop and commercialize them. Progenity will receive an ownership stake in the company. "Enumera Molecular was founded as a life science tools company focused on developing a scalab

      5/5/22 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Leadership Updates

    Live Leadership Updates

    See more

    $PROG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Adi Mohanty as Chief Executive Officer

      SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors. "As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success," said Eric d'Esparbes, Chief Financial Officer and interim CEO. "To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase o

      11/9/21 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

      SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi's medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. "As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems of the future. We are delighted that Surbhi Sarna has agreed to join the Progenity Board of Directors to support these efforts," said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder

      6/30/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Athyrium Opportunities Iii Co-Invest 1 Lp returned 42,362 units of Series X Preferred Stock to the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:55:13 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Kotzin Brian L. returned 44 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:20 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Mohanty Aditya P. returned 178 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables